中国同辐2024年度报告

（於中華人民共和國註冊成立的股份有限公司）(A joint stock company incorporated in thePeople’s Republic of China with limited liability)股份代號Stock Code：1763 CONTENTS Corporate Profile2Corporate Information4Definitions10Chairman’s Statement14Highlights of the Year18Development Status of the Nuclear TechnologyApplication Industry26Financial Highlights29Management Discussion and Analysis30Corporate Governance Report77Biographical Details of Directors, Supervisors andSenior Management111Directors’ Report123Supervisors’ Report173Independent Auditor’s Report178Consolidated Statement of Profit or Loss185Consolidated Statement of Profit or Loss and OtherComprehensive Income186Consolidated Statement of Financial Position187Consolidated Statement of Changes in Equity189Consolidated Statement of Cash Flows191Notes to the Consolidated Financial Statements194Five Year Summary355 CORPORATE PROFILE 1 7 6 31 9 8 33,36720241231201876 Founded in 1983, China Isotope & Radiation Corporation (stockcode: 1763,“CIRC”) is a leading enterprise in isotope andirradiation application in the PRC with 3,367 employees (as of 31December 2024), and was listed on the Main Board of the StockExchange on 6 July 2018. As a controlling subsidiary of ChinaNational Nuclear Corporation ( “CNNC”), CIRC is tasked with thedual mission of building a“strong nuclear power nation ” and a“healthy China”. It is the main force of CNNC ’s scientific andtechnological advancement for people ’s life and health and themain channel for the transformation of advanced nuclear scientificand technological achievements. 4266+N-60 With 42 years of experience in the nuclear technology applicationindustry, CIRC is the leading nuclear technology applicationenterprise in China, integrating research and development,production,sales and services,and is also a high-techenterprise with the most abundant products and the mostcomplete industrial chain in the field of isotope and its productsand irradiation processing in the world. Focusing on the twomajor industrial directions of nuclear healthcare and irradiationapplication, CIRC is committed to providing integrated solutionsfor nuclear medicine and radiotherapy, as well as radiationtechnology promotion and application, forming a “6+N” industriallayout with six major businesses as the core, including nuclides,nuclearmedicines,nuclear medical equipment,integratedsolution for nuclear medicine, radioactive source and application,and irradiation application. CIRC is the largest manufacturer ofimaging diagnostic and therapeutic radiopharmaceuticals, UreaBreath Test (UBT) kits and analyzers in China; the largest andmost complete manufacturer of radioactive sources in China;and the only service provider in China that covers the entireprocess of site selection, design, construction, source supplyand decommissioning of irradiation stations. CIRC has enteredthe field of high-end radiotherapy equipment in cooperation withone of the world ’s top three radiotherapy equipment suppliers,U.S. Accuray, focusing on the introduction, digestion, absorptionand re-innovation of high-end radiotherapy equipment, suchas spiral tomography system and radiosurgery robots. Throughindependent innovation, it has successfully developed a new fullydomesticated intelligent Cobalt-60 Gamma Beam StereotacticRadiotherapy System (Gamma Knife). CIRC is the only enterprisein China with a complete industrial chain of“source, equipment,station and application” for irradiation application, with the thirdlargest industrial scale in China. CORPORATE PROFILE(CONTINUED) 202412313771.8642023Tomo C As of 31 December 2024, the Company has formed a network of37 medical centres, with 7 R&D and production bases, servingmore than 18,000 medical institutions, serving more than 60million people annually, and supplying more than 40,000 sets ofancillary radioactive source equipment. In recent years, CIRC hasaccounted for nearly 70% of the large-scale Class A radiotherapyequipment approved and configured by the National HealthCommission, making it the No. 1 brand of Class A radiotherapyequipment. In 2023, Tomo C, a new type of first domestic doublehelix tomotherapy product in China ’s high-end healthcare field,was independently produced in large quantities. 6+N Looking forward, CIRC will focus on strengthening its corefunctions and enhancing its core competitiveness, focusingon playing the“three roles ” and striving to be the“threefront-runners”, making continuous improvements, pursuingexcellence, and comprehensively promoting the“6+N” industriallayout of nuclides, nuclear medicines, nuclear medical equipment,integrated solution for nuclear medicine, radioactive source andapplication, and irradiation application, with a view to buildingCIRC into a world-class isotope and irradiation technologyapplication product and service provider. CHINA ISOTOPE & RADIATION CORPORATION CORPORATE INFORMATION LEGAL NAME OF THE COMPANY (Abbreviation:) ENGLISH NAME OF THE COMPANY China Isotope & Radiation Corpo